Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive

SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive

These two 'hidden gems' in health care are set to rally, Jefferies says

Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Korro Bio (KRRO) and Incyte (INCY)

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting